Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients
1
7
EN
Fazlollah
Shokri
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
fazlollahshokriy@yahoo.com
N
Hamid
Ghaedi
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
hamidqaedi@yahoo.com
N
Soudeh
Ghafouri-Fard
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
soudeh-gh@yahoo.com
N
Abolfazl
Movafagh
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
a_movafagh@yahoo.com
N
Saeid
Abediankenari
Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
abediyan@yahoo.com
N
Abdolkarim
Mahrooz
Department of Clinical Biochemistry and Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
a-mahrooz@yahoo.com
N
Zahra
Kashi
Diabetes Research Center, Imam Teaching Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Zkashi@Mazums.ac.ir
N
Mir Davood
Omrani
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
davood_omrani@sbmu.ac.ir
Y
10.22088/acadpub.BUMS.5.1.1
Metabolic syndrome and its pathological sequel, type 2 diabetes are considered as important global health problems. Metformin is the most common drug prescribed for patients with this disorder. Consequently, understanding the genetic pathways involved in pharmacokinetics and pharmacodynamics of this drug can have a considerable effect on the personalized treatment of type 2 diabetes. In this study, we evaluated the association between rs11212617 polymorphism of ATM gene and rs628031 of SLC22A1 gene with response to treatment in newly diagnosed type 2 diabetes patients. We genotyped rs11212617 and rs628031 polymorphism by PCR based restriction fragment length polymorphism (RFLP) and assessed the role of this polymorphisms on response to treatment in 140 patients who have been recently diagnosed with type 2 diabetes and were under monotherapy with metformin for 6 months. Response to metformin was defined by HbA1c and fasting blood sugar (FBS) values. Based on such evaluations, patients were divided into two groups: responders (n= 63) and non-responders (n= 77). No significant association was found between these polymorphisms and response to treatment (OR= 0.86, [95% CI 0.52–1.41], P= 0.32) for rs11212617 and (OR= 0.45, [95% CI 0.64–1.76], P= 0.45) for rs 628031. The reported gene variants in ATM and SLC22A1 are not significantly associated with metformin treatment response in type 2 diabetic patients in an Iranian population.
Metformin, type 2 diabetes, pharmacogenetic
http://ijmcmed.org/article-1-414-en.html
http://ijmcmed.org/article-1-414-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
Zinc Finger 259 Gene Polymorphism rs964184 is Associated with Serum Triglyceride Levels and Metabolic Syndrome
8
18
EN
Seyed Reza
Mirhafez
Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mirhafezr@yahoo.com
N
Amir
Avan
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
amir_avan@yahoo.com
N
Alireza
Pasdar
Division of Applied Medicine, Medical School, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.
Pasdara@mums.ac.ir
N
Sara
Khatamianfar
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
monarch_371@yahoo.com
N
Leila
Hosseinzadeh
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
monarch_367@yahoo.com
N
Shiva
Ganjali
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
GanjaliSh931@mums.ac.ir
N
Ali
Movahedi
Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
N
Maryam
Pirhoushiaran
VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
N
Valentina
Gómez Mellado
VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
N
Domenico
Rosace
University of Bologna, Bologna, Italy.
N
Anne
van Krieken
Peter MacCallum Centre, St Andrew's Place, Melbourne, Australia.
N
Mahdi
Nohtani
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
N
Gordon
A. Ferns
Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.
N
Majid
Ghayour-Mobarhan
Department of Modern Science and Technologies; and Biochemistry of Nutrition Research Center; School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Y
10.22088/acadpub.BUMS.5.1.8
Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors that include: abdominal obesity, dyslipidaemia, hypertension, insulin resistance and impaired glucose tolerance. Recent genome wide association studies have identified several susceptibility regions involved in lipid metabolism that are also associated with MetS. We have explored the association of 9 genetic polymorphisms involved in lipid metabolism and hypertension, including: MTHFR C677T, SELE L554F, FGB - 455G>A, GNB3 C825T, ZNF259 C>G, PSRC-1 A>G, CETP I405V, LPL S447X and LPA C>T in 97 subjects with mets and 96 individuals without MetS who were recruited randomly from Mashhad stroke and heart atherosclerotic disorder (MASHAD) study using a stratified cluster random sampling technique. Anthropometric parameters and biochemical measurements were determined in all the subjects. Genotyping was carried out followed by univariate and multivariate analyses. The subjects with MetS had a higher triglyceride and lower HDL- C. CG+ GG genotypes of ZNF259 polymorphism (rs964184 C>G) and TT+CT genotypes of MTHFR C677T (rs1801133) were associated with MetS, and individuals carrying the G allele for ZNF259 or the T allele for MTHFR polymorphisms were associated with MetS (e.g, odds ratio (OR) for CG+GG genotypes vs. CC wild type: 2.52, CI=1.33-4.77; P=0.005). However, after multiple comparison adsustments, this relationship remained significant only for CG+ GG genotypes of ZNF259 polymorphism. Moreover, the ZNF259 CG+ GG genotypes were associated with increased serum concentrations of triglycerides and LDL-C, compared to the wild type. These data support the necessity of further studies in larger multicenter settings.
Metabolic syndrome, gene polymorphisms, lipid pathway
http://ijmcmed.org/article-1-428-en.html
http://ijmcmed.org/article-1-428-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
The Genotoxic and Cytotoxic Effects of Bisphenol-A (BPA) in MCF-7 Cell Line and Amniocytes
19
29
EN
Seyed Mohsen
Aghajanpour-Mir
Cellular & Molecular Biology Research Center, Health Institute, Babol University of Medical Sciences, Babol, Iran.
mohsenaghajanpour@gmail.com
N
Ebrahim
Zabihi
Cellular & Molecular Biology Research Center, Health Institute, Babol University of Medical Sciences, Babol, Iran.
e_zabihi@yahoo.com
N
Elahe
Keyhani
Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
ekeyhani1058@gmail.com
N
Haleh
Akhavan-Niaki
Cellular & Molecular Biology Research Center, Health Institute, Babol University of Medical Sciences, Babol, Iran.
halehakhavan@yahoo.com
N
Iman
Bagherizadeh
Department of Medical Genetics and Sarem Cell Research Center (SCRC), Sarem Women’s Hospital, Tehran, Iran.
imanimoni@gmail.com
N
Sajjad
Biglari
Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
N
Farkhondeh
Behjati
Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
fbehjati@gmail.com
Y
10.22088/acadpub.BUMS.5.1.19
Bisphenol-A (BPA) is an industrial xenoestrogen used widely in our living environment. Recently, several studies suggested that BPA has destructive effects on DNA and chromosomes in normal body cells via estrogen receptors (ER). Therefore, BPA could be considered as an important mediator in many diseases such as cancer. However, there are still many controversial issues which need clarification. In this study, we investigated the BPA-induced chromosomal damages in MCF-7 cell line, ER-positive and negative amniocyte cells. Cytotoxicity and genotoxicity effects of BPA were also compared between these three cell groups. Expression of estrogen receptors was determined using immunocytochemistry technique. The cell cytotoxicity of BPA was measured by MTT assay. Classic cytogenetic technique was carried out for the investigation of chromosome damage. BPA, in addition to cytotoxicity, had remarkable genotoxicity at concentrations close to the traceable levels in tissues or biological fluids. Although some differences were observed in the amount of damages between ER-positive and negative fetal cells, interestingly, these differences were not significant. The present study showed that BPA could lead to chromosomal aberrations in both ER-dependent and independent pathways at some concentrations or in cell types yet not reported. Also, BPA could probably be considered as a facilitator for some predisposed cells to be cancerous by raising the chromosome instability levels. Finally, estrogen receptor seems to have a different role in cytotoxicity and genotoxicity effects.
Bisphenol-A (BPA), estrogen receptor, MCF-7, amniocyte, chromosome abnormality, classic cytogenetics
http://ijmcmed.org/article-1-335-en.html
http://ijmcmed.org/article-1-335-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel
30
36
EN
Pouria
Mohammadi
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
pouria1987m@yahoo.com
N
Massoud
Saidijam
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
seyedo2@yahoo.com
N
Arastoo
Kaki
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
mzijoud@yahoo.com
N
Katayoon
Etemadi
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
zijoud7@yahoo.com
N
Nooshin
Shabab
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
seyedo2@yahoo.com
N
Reza
Yadegarazari
Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
reza.yadegarazari@yahoo.com
Y
10.22088/acadpub.BUMS.5.1.30
Colorectal cancer remains one of the major cancer- related deaths despite progress in the treatment during past decades. Detection of disease at earlier stages reduces its mortality. The aim of current study was to investigate expression of Cytokeratin 19 (CK19), Cytokeratin 20 (CK20) and Guanylyl Cyclase C (GCC) mRNA in peripheral blood of non- metastatic colorectal cancer patients which may result into introducing of an early detection test. 25 patients with colorectal cancer and 25 healthy controls were recruited. Blood was obtained from all individuals. Expression of CK19 and CK20 and GCC mRNA and 18SrRNA (as reference gene) were determined based on real- time RT-PCR on total RNA from blood. CK19, CK20 and GCC expression had been detected in 68%, 76% & 52% of patient group, respectively, which was higher than healthy group, with 8%, 32% and 0% expression, respectively (p<0.05). CK20 was over-expressed 8- fold more in patients compared to controls. Similar result was found for CK19 with 4- fold over- expression. Sensitivity and specificity of combination of markers were 88% and 68%, respectively. Current data suggest that the detection of CK20 & CK19 as relative sensitive markers may become a valuable tool for primary diagnosis of colorectal cancer in early stages. GCC could be considered as a specific tumor marker for detection of colorectal cancer. Higher expression of these markers in patients may be considered as a relative good tool for the diagnosis of disease in non- metastatic stages.
Colorectal cancer, cytokeratin 19, cytokeratin 20, guanylyl cyclase C, biomarker
http://ijmcmed.org/article-1-415-en.html
http://ijmcmed.org/article-1-415-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
High Yield Overexpression, Refolding, Purification and Characterization of Pseudomonas aeruginosa Type B-Flagellin: An Improved Method Without Sonication
37
48
EN
Sobhan
Faezi
Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
sobhan.faezi@gmail.com
N
Ahmad Reza
Bahrmand
Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Padideh79@yahoo.com
Y
Mehdi
Mahdavi
Departments of Immunology, Pasteur Institute of Iran, Tehran, Iran.
mahdavivac@gmail.com
N
Seyed Davar
Siadat
Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
siadat@pasteur.ac.ir
N
Iraj
Nikokar
Laboratory of Microbiology and Immunology of Infectious Diseases, Paramedicine Faculty, Guilan University of Medical Sciences, Guilan, Iran.
marya4030@yahoo.com
N
Soroush
Sardari
Biotechnology Research Center, Drug Design and Bioinformatics Group, Pasteur Institute of Iran, Tehran, Iran.
ssardari@hotmail.com
N
Ian Alan
Holder
Departments of Microbiology and Surgery, College of Medicine, University of Cincinnati, and Shriners Burns Institute, Cincinnati, Ohio, USA.
iaholder@juno.com
N
10.22088/acadpub.BUMS.5.1.37
Pseudomonas aeruginosa as an opportunistic pathogen is a significant cause of acute and chronic infections in patients with compromised defenses. This bacterium is motile via a single polar flagellum made of polymerized flagellin subunits differentiated into two major serotypes: A and B. flagellin plays an important role as a virulence factor in the adhesion, colonization and invasion of P. aeruginosa into host epithelial cells. To develop a functional vaccine that can be used in practical application to prevent and treat infection, type B-flagellin was produced as recombinant protein. In this work, the fliC gene was introduced into a pET28a vector and expressed in Escherichia coli BL21 (DE3). The expressed recombinant protein was purified by a modified method without sonication using a HisTrap affinity column. The functional activities of produced flagellin were confirmed by ELISA, western blot analysis, motility inhibition assay and opsonophagocytosis test. The purification process of the type B-flagellin was lead to a high yield. The produced recombinant type B-flagellin showed high biological activity in all of these standard assays. In conclusions, this report provides the new protocol to efficiently obtain the type B-flagellin with high biological activity and immunogenicity. This immunogen can be introduced as an adjuvant or vaccine in the future study.
Pseudomonas aeruginosa, flagellin protein, pET28a, purification, vaccine
http://ijmcmed.org/article-1-437-en.html
http://ijmcmed.org/article-1-437-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
Orosomucoid-1 Expression in Ameloblastoma Variants
49
56
EN
Alejandro
García-Muñoz
Laboratorio de Investigación en Odontología, ALMARAZ/UBIMED, FES Iztacala, UNAM. State of Mexico, Mexico.
alexandro_06uam@yahoo.com.mx
N
Ronell
Bologna-Molina
Molecular Pathology, Universidad de la República (UDELAR), Montevideo, Uruguay.
ronellbologna@hotmail.com
N
Mario A.
Rodríguez
Department of Infectomics and Molecular Pathogenesis, CINVESTAV-IPN, México, D.F, México.
marodri@cinvestav.mx
N
Rodrigo
Liceaga-Reyes
Maxillofacial Surgery Department. Hospital Juárez de México, México D.F, México.
r_liceaga@hotmail.com
N
Jose Eduardo
Farfán-Morales
Instituto Nacional de Pediatría, México D.F, México.
farfanedu@yahoo.com.mx
N
Saray
Aranda-Romo
Biochemistry, Microbiology and Pathology Laboratory, Faculty of Stomatology, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
aran_sa77@hotmail.com
N
Nelly
Molina-Frechero
Health Care Department, Universidad Autónoma Metropolitana, Xochimilco, UAM, México City, Mexico.
nmolinaf@hotmail.com
N
Rogelio
González-González
Department Research, School of Dentistry, Universidad Juárez del Estado de Durango, México.
rogegg@hotmail.com
Y
10.22088/acadpub.BUMS.5.1.49
Odontogenic tumors constitute a group of heterogeneous lesions of benign and malignant neoplasms with variable aggressiveness. Ameloblastomas are a group of benign but locally invasive neoplasms that occur in the jaws and are derived from epithelial elements of the tooth-forming apparatus. We previously described orosomucoid-1 protein expression in odontogenic myxomas. However, whether orosomucoid-1 is expressed in other odontogenic tumors remains unknown. Since orosomucoid-1 belongs to a group of acute-phase proteins and has many functions in health and disease, we identified and analyzed orosomucoid-1 expression in ameloblastoma variants and ameloblastic carcinoma using western blot and immunohistochemical techniques. Thirty cases of ameloblastoma were analyzed for orsomucoid-1; five specimens were fresh for western blot study (four benign ameloblastomas and one ameloblastic carcinoma), and 25 cases of benign ameloblastoma for immunohistochemical assays. Orosomucoid-1 was widely expressed in each tumor variant analyzed in this study, and differential orosomucoid-1 expression was observed between benign and malignant tumor. Orosomucoid-1 may play an important role in the behavior of ameloblastomas and influence the biology and development of the variants of this tumor.
Orosomucoid-1, ameloblastoma, ameloblastic carcinoma, odontogenic tumors
http://ijmcmed.org/article-1-420-en.html
http://ijmcmed.org/article-1-420-en.pdf
Babol University of Medical Sciences
International Journal of Molecular and Cellular Medicine (IJMCM)
2251-9637
2251-9645
5
1
2016
2
1
Practice of Consanguinity and Unusual Cases of Inherited Familial Chromosome Abnormalities: A Case Report
57
64
EN
Debarshi
Sanyal
Lilac Insight Pvt Ltd, Ambience Court, 19th Floor, Unit 1901 & 1902, Sec-19 Vashi, Navi Mumbai 400705 Maharashtra, India.
jupiterdev@gmail.com
Y
Vidya
Bhairi
Lilac Insight Pvt Ltd, Ambience Court, 19th Floor, Unit 1901 & 1902, Sec-19 Vashi, Navi Mumbai 400705 Maharashtra, India.
vbhairi@gmail.com
N
Jayarama
S Kadandale
Centre For Human Genetics, Biotech Park, Electronic City, Phase- I, Bangalore-560100, Karnataka, India.
jayaram@ibab.ac.in
N
10.22088/acadpub.BUMS.5.1.57
We present 2 cases of likely rare event. In case 1, 3rd degree consanguineous marriage revealed inv(6) with same break points in parents who were found to be phenotypically normal. The same inv(6) being inherited in progeny but presented with low AMH (anti Mullerian hormone) and high level of FSH (follicular stimulating hormone) leading to polycystic ovarian syndrome/premature ovarian failure. In case 2, a couple was presented with 2nd degree consanguineous marriage and referred for 2 recurrent/ missed abortions. The amounts of shared genes are suggestive of more lethal genetic outcomes and inferred endogamy is a major driver to reproductive fiascoes, the ancestries of which are deeply tied at the meiotic level.
Consanguinity, endogamy, inversion, familial translocations, conventional cytogenetics
http://ijmcmed.org/article-1-433-en.html
http://ijmcmed.org/article-1-433-en.pdf